Total Payments
$149,172
2021 Payments
$2,952
Companies
11
Transactions
183
Medicare Patients
142
Medicare Billing
$18,178
Payment Breakdown by Category
Consulting$105,626 (70.8%)
Travel$25,807 (17.3%)
Research$8,761 (5.9%)
Other$5,363 (3.6%)
Food & Beverage$3,616 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $105,626 | 31 | 70.8% |
| Travel and Lodging | $25,807 | 53 | 17.3% |
| Unspecified | $8,761 | 13 | 5.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,363 | 17 | 3.6% |
| Food and Beverage | $3,616 | 69 | 2.4% |
Payments by Type
General
$140,411
170 transactions
Research
$8,761
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $35,964 | 31 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $34,925 | 32 | $0 (2020) |
| AbbVie, Inc. | $30,026 | 49 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $14,188 | 3 | $0 (2019) |
| F. Hoffmann-La Roche AG | $12,054 | 29 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $5,077 | 7 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $4,924 | 9 | $0 (2019) |
| Genentech USA, Inc. | $4,840 | 10 | $0 (2019) |
| AstraZeneca UK Limited | $3,478 | 9 | $0 (2020) |
| Genentech, Inc. | $2,447 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $2,952 | 3 | F. Hoffmann-La Roche AG ($2,952) |
| 2020 | $35,759 | 26 | AstraZeneca Pharmaceuticals LP ($19,145) |
| 2019 | $67,968 | 68 | Bayer HealthCare Pharmaceuticals Inc. ($19,187) |
| 2018 | $24,794 | 57 | AbbVie, Inc. ($9,826) |
| 2017 | $17,700 | 29 | AbbVie, Inc. ($17,700) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,536.87 | Research |
| Study: A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS, AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT P | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $315.89 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $99.24 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $129.53 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $122.72 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $122.72 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 07/07/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $448.56 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 06/26/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| Category: Oncology | ||||||
| 06/22/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 06/16/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 06/11/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $3,055.00 | General |
| Category: Oncology | ||||||
| 04/24/2020 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $396.85 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $181.55 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 02/12/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Travel and Lodging | In-kind items and services | $5,249.02 | General |
| Category: Oncology | ||||||
| 01/23/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $6,850.00 | General |
| Category: Oncology | ||||||
| 01/17/2020 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $430.37 | General |
| Category: Oncology | ||||||
| 01/17/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $270.07 | General |
| Category: Oncology | ||||||
| 01/17/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 01/17/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $76.00 | General |
| Category: Oncology | ||||||
| 01/17/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $47.82 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS, AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT P | F. Hoffmann-La Roche AG | $2,537 | 1 |
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 | F. Hoffmann-La Roche AG | $1,636 | 7 |
| AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | F. Hoffmann-La Roche AG | $415.13 | 2 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult | F. Hoffmann-La Roche AG | $122.72 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 5 | 142 | 248 | $86,325 | $18,178 |
Total Patients
142
Total Services
248
Medicare Billing
$18,178
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 36 | 82 | $26,232 | $5,669 | 21.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 50 | $23,580 | $3,814 | 16.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 34 | $15,164 | $3,362 | 22.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 22 | 29 | $4,437 | $2,029 | 45.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 13 | 22 | $13,090 | $2,022 | 15.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 19 | $1,938 | $865.44 | 44.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 11 | 12 | $1,884 | $416.12 | 22.1% |
About Anna Farago, MD, PHD
Anna Farago, MD, PHD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1114185527.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Anna Farago, MD, PHD has received a total of $149,172 in payments from pharmaceutical and medical device companies, with $2,952 received in 2021. These payments were reported across 183 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($105,626).
As a Medicare-enrolled provider, Farago has provided services to 142 Medicare beneficiaries, totaling 248 services with total Medicare billing of $18,178. Data is available for 1 year (2020–2020), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 06/02/2008
- Last Updated 02/18/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114185527
Products in Payments
- Vitrakvi (Drug) $30,736
- IMFINZI (Drug) $26,285
- Non-Covered Product (Drug) $7,624
- TAGRISSO (Drug) $6,850
- TECENTRIQ (Biological) $6,119
- Non-Covered $2,191
- ROZLYTREK (Biological) $1,759
- TALZENNA (Drug) $1,250
- KEYTRUDA (Biological) $577.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795